Launching new products, services. . . Aspen Aspen Neuroscience (CA, USA; www.aspenneuroscience.com) has announced its launch following a US$ 6.5 million seed round to develop the first autologous cell therapies for Parkinson's disease [5] . The company's research is specific to induced pluripotent stem cells, which it develops by taking a skin biopsy from a person with Parkinson's disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person, thereby restoring the types of neurons lost in Parkinson's disease. Aspen's lead product (ANPD001) is currently undergoing investigational new drug-enabling studies for the treatment of sporadic Parkinson's disease. Aspen is also developing a gene-edited autologous neuron therapy (ANPD002) that is in the research stage and targeted toward familial forms of Parkinson's disease, beginning with the most common genetic variant in the gene encoding glucocerebrosidase. Aspen leverages proprietary machine-learning tools and AI to ensure quality control during manufacturing and to deliver a safe and reproducible product for each cell line.
The National Stem Cell Foundation (KY, USA; https://nationalstemcellfoundation.org/) funded collaboration between researchers at the New York Stem Cell Foundation Research Institute (NY, USA; https://nyscf.org/research -institute/) and Aspen Neuroscience will send a first-in-kind study of neurodegenerative disease to the International Space Station (ISS) on the 19th SpaceX Commercial Resupply Services (CRS-19) mission to study Parkinson's disease and primary progressive multiple sclerosis in microgravity [6] .
Jasper
Jasper Therapeutics (CA, USA; www.jaspertherapeutics.com), a new biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants (HSCT) and gene therapies, has announced the launch of the company with a US$ 35 million total Series A financing [7] . The proceeds will be used to advance the clinical development of the company's lead product candidate, JSP191, which is designed to replace or reduce the toxicity of chemotherapy and radiation therapy as a conditioning regimen to prepare patients for hematopoietic cell transplant. Jasper's development of JSP191 is also supported by a collaboration with the California Institute for Regenerative Medicine (CA, USA; www.cirm.ca.gov), which has been funding the program and is committed to providing a total of US$ 23 million in grant support. As part of the Series A financing, Amgen (CA, USA: www.amgen.com), which discovered JSP191 (formerly AMG191), has licensed worldwide rights to Jasper that also include translational science and materials from Stanford University.
JSP191 is a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow. JSP191 binds to human CD117, a receptor for stem cell factor (SCF) that is expressed on the surface of hematopoietic stem and progenitor cells. The interaction of SCF and CD117 is required for stem cells to survive. JSP191 blocks SCF from binding to CD117 and disrupts critical survival signals, causing the stem cells to undergo cell death and create an empty space in the bone marrow for donor or gene-corrected transplanted cells to engraft. . To date, JSP191 has been evaluated in more than 80 healthy volunteers and patients. It is currently being evaluated as a sole conditioning agent in a Phase I doseescalation trial to achieve donor stem cell engraftment in patients undergoing hematopoietic cell transplant for severe combined immunodeficiency, which is curable only by this type of treatment (www.clinicaltrials.gov; ID: NCT02963064). Clinical development of JSP191 will be expanded to also study patients with acute myeloid leukemia or myelodysplastic syndrome who are receiving hematopoietic cell transplant.
Clinical trials

T cells Bristol-Myers Squibb
Bristol-Myers Squibb (NJ, USA; www.bms.com) has announced that the pivotal study of lisocabtagene maraleucel (liso-cel), an investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy with a defined composition of purified CD8 + and CD4 + CAR T cells in relapsed/refractory large B-cell lymphomas (TRANSCEND NHL 001; https://clinicaltrials.gov; ID: NCT03361748), met its primary and secondary end points while demonstrating durable responses [8] . In the study, 344 patients were leukapheresed and 269 patients received liso-cel at one of three dose levels (50 × 10 6 n = 51; 100 × 10 6 n = 177; and 150 × 10 6 n = 41). There were 25 patients that received nonconforming product and there were two instances where product could not be manufactured. There were neurologic events that occurred in 30% of patients (80/269) with grade 3 or higher neurologic events occurring in 10% (27/269) of patients at a median onset of 9 days. 19 and 21% of patients received tocilizumab and corticosteroids, respectively. There were four grade 5 TEAEs related to liso-cel in the study from diffuse alveolar damage, pulmonary hemorrhage, multiple organ dysfunction syndrome or cardiomyopathy. There were three grade 5 TEAEs considered unrelated to liso-cel from fludarabine leukoencephalopathy, septic shock and progressive multifocal leukoencephalopathy. Eight patients had ongoing CRS/NE at the time of death from other reasons. Prolonged grade 3 or higher cytopenias were reported in 37% (100/269) of patients. Bristol-Myers Squibb is the submitting a Biologics License Application to the US FDA based on results from the TRANSCEND NHL 001 study.
Bristol-Myers Squibb & bluebird
Bristol-Myers Squibb (www.bms.com) and Bluebird Bio (MA, USA; www.bluebirdbio.com) have announced positive top-line results from KarMMa (https://clinicaltrials.gov; ID: NCT03361748), an open-label, single arm, multicenter, Phase II study of idecabtagene vicleucel (ide-cel; bb2121) [9] . KarMMa, which evaluated the efficacy and safety of the companies' lead investigational B cell maturation antigen (BCMA)-targeted CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma, met its primary end point and key secondary end point. KarMMa enrolled 140 patients, of whom 128 patients were treated with ide-cel across the target dose levels of 150-450 × 106 CAR + T cells. All treated patients were exposed to at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and all were refractory to their last regimen. Results for the primary end point (ORR) and key secondary end point (complete response rate), as well as DOR and PFS across the target dose levels and at each of the three target doses explored in the study are presented in the table below. The median follow-up duration for all subjects was 11.3 months. Median DOR and median PFS are not reported for the 150 × 10 6 CAR + T cells dose group due to the small number of evaluable patients (Table 1) . They have also announced updated safety and efficacy results from the ongoing Phase I study (CRB-402) of bb21217, an investigational BCMA-targeted CAR T cell therapy being studied in patients with relapsed/refractory multiple myeloma (https://clinicaltrials.gov; ID: NCT03274219) [10] . bb21217 is an investigational BCMAtargeted CAR T cell therapy that uses the ide-cel (bb2121) CAR molecule and is cultured with the PI3 kinase inhibitor (bb007) to enrich for T cells displaying a memory-like phenotype with the intention to increase the in vivo persistence of CAR T cells. Early data from the CRB-402 study in heavily pretreated R/RMM patients (median of six prior lines) demonstrate the potential for durable responses following bb21217 CAR T cell treatment, with a median DOR of 11.1 months at the 150 × 10 6 CAR + T cell dose level. Consistent with the hypothesis underlying the bb21217 program that memory-like phenotype T cells may survive longer in vivo, we have observed durable CAR T cell persistence in evaluable patients (n = 2/2) with ongoing response at up to 18 months following treatment. They are continuing to recruit additional patients in the study and performing ongoing assessments of the functional persistence of bb21217, as well as its potential correlation to durability of response. CRB-402, the first in-human study of bb21217 in patients with relapsed/refractory multiple myeloma, is designed to assess the primary end point of safety as well as other predefined end points including efficacy and pharmacokinetics measurements. CRB-402 is a two-part, open-label, multi-site Phase I study of bb21217 in adults with relapsed/refractory multiple myeloma with a projected final enrollment of 74 patients. The dose escalation part of CRB-402 is complete, and the dose expansion part of the study is ongoing.
Celularity
Celularity (NJ, USA; www.celularity.com), a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies derived from postpartum human placentas, announced data introducing an extensive platform in genetically modified natural killer (NK)-and T cell-based programs, and highlighting long-term safety and efficacy results from the Phase I study of PNK-007 in patients with multiple myeloma (https://clinicaltrials.gov; ID: NCT02955550) [11] . Results from a Phase I clinical study evaluating PNK-007 in patients with multiple myeloma demonstrated a single infusion of PNK-007 was well tolerated after autologous stem cell transplant for up to 1 year. PNK-007 is a first-generation investigational allogeneic off-the-shelf NK cell therapy. No serious adverse events were attributable to PNK-007, and no dose-limiting toxicity, graft-versus-host disease (GvHD), cytokine release syndrome, graft failure or graft rejection was observed. PNK-007 is the only allogeneic, off-the-shelf NK cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. When derived from the placenta, these cells offer intrinsic safety and versatility, allowing potential use across a range of organs and tissues. PNK cells are currently being investigated as a treatment for acute myeloid leukemia and multiple myeloma.
Gamida Cell
Gamida Cell (Israel; www.gamida-cell.com), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, has announced updated results from a Phase I clinical study of GDA-201, an investigational, NK cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma and multiple myeloma [12] . Data from 22 patients in the ongoing study showed GDA-201 in combination with monoclonal antibodies was generally well tolerated and demonstrated early evidence of clinical activity in heavily pretreated patients, including five complete responses observed among nine patients with NHL. Gamida Cell plans to initiate a Phase I/II multi-dose, multi-center study of GDA-201 in patients with non-Hodgkin lymphoma in 2020.
Other Alpine
Alpine Immune Sciences (WA, USA; www.alpineimmunesciences.com), a clinical-stage immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, presented Phase I data from the healthy volunteer study of ALPN-101, a first-in-class dual CD28/ICOS antagonist, and details on its upcoming Phase I/II BALANCE study of ALPN-101 in steroid-resistant or steroid-refractory acute GvHD (https://clinicaltrials.gov; ID: NCT04227938) [13] . ALPN-101 is a novel Fc fusion protein of a human inducible T cell co-stimulator ligand variant immunoglobulin domain (vIgD™), and a first-in-class therapeutic designed to inhibit simultaneously the CD28 and ICOS inflammation pathways. CD28 and ICOS are closely related costimulatory molecules with partially overlapping roles in T-cell activation likely playing a role in multiple autoimmune and inflammatory diseases. In adult healthy volunteers, ALPN-101 has been well tolerated as single intravenous or subcutaneous doses, without cytokine release, infusion-related reactions, hypersensitivity or other signs of agonist activity. Dose-dependent pharmacodynamic activity was observed, including inhibition of T-cell activation, assessed ex vivo based on inhibition of staphylocococcal entereotoxin B-induced cytokine production, and inhibition of antibody responses, assessed following immunization with keyhole limpet hemocyanin. Based on activity in models, together with favorable tolerability and pharmacodynamics in healthy volunteers, ALPN-101 has the potential to be a clinically meaningful immunomodulator for the treatment of inflammatory diseases such as GvHD. BALANCE is a Phase I/II, first-in-disease dose escalation and expansion study of ALPN-101 in patients with active, steroid-refractory or steroid-resistant acute GvHD. It will explore the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of ALPN-101.
Follica
Follica (MA, USA; www.follicabio.com), a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other medical indications, has announced top line results from its safety and efficacy optimization study to treat hair loss in male androgenetic alopecia [14] . The study was designed to select the optimal treatment regimen using Follica's proprietary device in combination with a topical drug and successfully met its primary end point. The selected treatment regimen demonstrated a statistically significant 44% improvement of visible (nonvellus) hair count after 3 months of treatment compared with baseline (n = 19; p < 0.001). Across all three treatment arms, the overall improvement of visible (nonvellus) hair count after 3 months of treatment was 29% compared with baseline (n = 48; p < 0.001), reflecting a clinical benefit across the entire study population and a substantially improved outcome seen with the optimal treatment regimen. Additionally, a prespecified analysis comparing the 44% change in visible (nonvellus) hair count to a 12% historical benchmark set by approved pharmaceutical products established statistical significance (p = 0.005). The initiation of a Phase III registration study is expected in the first half of 2020. Follica's proprietary in-office treatment regimen combines targeted scalp disruption using the Follica Hair Follicle Neogenesis device, with a topical on-market drug to create and grow new hair follicles.
WindMIL
WindMIL Therapeutics (MD, USA; https://windmiltx.com), a clinical-stage company developing marrowinfiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced that the first patient has been dosed in a Phase IIa clinical trial to determine the safety and efficacy of MILs alone and in combination with an anti-PD-1 in patients with locally advanced unresectable or metastatic non-small-cell lung cancer (NSCLC) who are refractory to or have relapsed on an anti-PD-1-containing regimen (https://clinicaltrials.gov; ID: NCT04069936) [15] . This open-label, multi-center study will assess the safety and efficacy of MILs alone and in combination with an anti-PD-1. MILs -NSCLC™ is an adoptive cell therapy product produced via WindMIL's proprietary process to activate and expand T cells derived from the bone marrow of NSCLC patients. The first three to six patients in this Phase IIa study will be treated with MILs-NSCLC only. Thereafter, the study protocol calls for approximately 20 patients to be treated with MILs-NSCLC plus an anti-PD-1 product. The study's primary end point is objective response rate. MILs are developed through a proprietary process to activate and expand memory T cells found in the bone marrow into MILs. Because memory T cells in bone marrow occur as a result of the immune system's recognition of tumor antigens, MILs are specifically suited for adoptive cellular immunotherapy and directly eradicate or facilitate eradication of each patient's unique cancer. WindMIL is currently studying use of MILs to treat patients with multiple myeloma, NSCLC, squamous cell carcinoma of the head and neck and glioblastoma, and plans to expand into other solid tumors. To date, more than 100 patients have received treatment with MILs and ongoing studies continue to build upon the favorable safety profile and promising efficacy seen in early development.
Regulations, approvals, acquisitions. . .
Green light Abeona
Abeona Therapeutics (NY, USA; www.abeonatherapeutics.com) has announced that the FDA has removed its clinical hold and provided clearance to proceed with the VIITAL™ study, the Company's pivotal Phase III clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disorder of Type VII collagen deficiency without an approved therapy [16] . The FDA removed the clinical hold following the Company's submission of additional data points on transport stability of EB-101 to clinical sites. Abeona expects to initiate the VIITAL™study in first quarter of 2020. The VIITAL Phase III study will be a multi-center, randomized clinical trial assessing EB-101 in 10 to 15 RDEB patients, with approximately 30 chronic wound sites treated in total. The primary study end point will be the proportion of wounds with greater than 50% healing at 3 months, comparing treated with untreated wound sites on the same patient. Secondary end points include the patient's global impression of change in pain from baseline as well as other patient reported outcomes assessing pain during dressing changes, pain impact and physical function. EB-101 is an autologous, gene-corrected cell therapy in late-stage clinical development for the treatment of RDEB, a rare connective tissue disorder without an approved therapy. Treatment with EB-101 involves using gene transfer to deliver COL7A1 genes into a patient's own keratinocytes and transplanting them back to the patient to enable normal Type VII collagen expression and facilitate wound healing. In the USA, Abeona holds Regenerative Medicine Advanced Therapy, Breakthrough Therapy and Rare Pediatric designations for EB-101 and Orphan Drug designation in both the USA and EU.
Adaptimmune Adaptimmune Therapeutics (UK; www.adaptimmune.com) has received Regenerative Medicine Advanced Therapy designation from the FDA for ADP-A2M4 for the treatment of synovial sarcoma [17] . Earlier this year, FDA to ADP-A2M4 for the treatment of soft tissue sarcomas. The Company's unique Specific Peptide Enhanced Affinity Receptor T-cell platform enables the engineering of T cells to target and destroy cancer across multiple solid tumors. ADP-A2M4 is a therapeutic candidate in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial, head and neck, ovarian, non-small cell lung, esophageal, synovial sarcoma, myxoid round cell liposarcoma and gastric cancers expressing MAGE-A4.
Bristol-Myers Squibb
Bristol-Myers Squibb (www.bms.com) has announced that the FDA has granted Breakthrough Therapy Designation for ORENCIA (abatacept) for the prevention of moderate-to-severe acute GvHD in HSCTs from unrelated donors [18] . There are no approved therapies for the prevention of acute GvHD, a potentially life-threatening medical complication that can impact patients receiving such transplants for the treatment of certain genetic diseases and hematologic cancers. Stem cell transplant infusions include donor T cells, a type of white blood cell that recognizes and destroys foreign invaders in the recipient's body including cancer cells. GvHD occurs when the donor T cells also recognize the patient's healthy cells as foreign and start attacking healthy tissues and organs. T-cell activation requires a signaling process called costimulation. ORENCIA, a therapy currently approved to treat various arthritic conditions, binds to and inhibits protein targets involved in costimulation, thus inhibiting T-cell activation. Acute GvHD impacts up to 40% of patients who receive stem cell transplants from unrelated and HLA-mismatched donors.
CASI
The China National Medical Product Administration (http://english.nmpa.gov.cn) has approved CASI Pharmaceuticals' (MD, USA; www.casipharmaceuticals.com) clinical trial applications for CNCT19 (CD19 CAR-T) in relapsed/refractory B-cell acute lymphoblastic and B-cell non-Hodgkin lymphoma submitted by its partner Juventas Cell Therapy (China; www.juventas.cn/en/about.html) [19] . The Company expects to start enrolling patients in early 2020. CASI has previously acquired exclusive worldwide commercial rights to CNCT19 from Juventas.
Janssen
The Janssen Pharmaceutical Companies of Johnson & Johnson (NJ, USA; www.janssen.com) has announced that the FDA has granted Breakthrough Therapy Designation for JNJ-68284528 (JNJ-4528), an investigational BCMA-directed CAR-T therapy in previously treated patients with multiple myeloma [20] . The Breakthrough Therapy Designation is supported by data from the Phase Ib/II CARTITUDE-1 study (https://clinicaltrials.gov; ID: NCT03548207), an open-label, multicenter clinical trial evaluating the safety and efficacy of JNJ-4528 in adults with relapsed or refractory multiple myeloma. The ORR included 69% of patients achieving a complete response (CR) or better (66% achieving a stringent CR); 86% of patients achieving a very good partial response or better; and 14% of patients achieving a partial response. In addition, 100% of evaluable patients achieved early minimal residual disease-negative disease status at day 28 postinfusion. At the six-month follow-up, 27 of 29 patients were progression-free. Based on the Phase Ib results, a recommended Phase II dose of 0.75 × 10 CAR+ viable T cells/kg was confirmed.
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